Gilead Sciences (GILD) Shareholder's Equity Growth (1y) (2010 - 2026)

Gilead Sciences (GILD) Shareholder's Equity Growth (1y) (2010 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 23.26%
Dec 31, 2025 17.96%
Sep 30, 2025 17.13%
Jun 30, 2025 7.66%
Mar 31, 2025 9.30%
Dec 31, 2024 -15.40%
Sep 30, 2024 -17.32%
Jun 30, 2024 -13.73%
Mar 31, 2024 -16.64%
Dec 31, 2023 7.26%
Sep 30, 2023 5.63%
Jun 30, 2023 4.35%
Mar 31, 2023 5.14%
Dec 31, 2022 0.69%
Sep 30, 2022 -1.93%
Jun 30, 2022 2.56%
Mar 31, 2022 5.01%
Dec 31, 2021 15.60%
Sep 30, 2021 22.90%
Jun 30, 2021 8.64%